FILANA THERAPEUTICS, INC. - 8-K Filing
Filana Therapeutics reports Q3 2026 net loss of $10.7 million and announces FDA clinical hold lift for simufilam in TSC-related epilepsy. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $SAVA